Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD

BACKGROUND: Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies represents an established treatment for patients with severe eosinophilic asthma (SEA) but did not show clinical efficacy in patients with COPD. The objective of the present study was to evaluate treatment res...

Descripción completa

Detalles Bibliográficos
Autores principales: Drick, Nora, Fuge, Jan, Seeliger, Benjamin, Speth, Milan, Vogel-Claussen, Jens, Welte, Tobias, Suhling, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original research articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589335/
https://www.ncbi.nlm.nih.gov/pubmed/36299360
http://dx.doi.org/10.1183/23120541.00207-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589335/
https://www.ncbi.nlm.nih.gov/pubmed/36299360
http://dx.doi.org/10.1183/23120541.00207-2022

Ejemplares similares